Leigh Brody

Leigh joins the UCL Technology fund after ten years of experience in the life sciences.

Having started as a bench scientist at the Broad Institute, she went on to do a PhD in Biomedical Sciences, which led her into industry after a technology she developed was the basis for a spin-out company.

She later went on to help build the commercial technologies of a CRISPR gene editing company eventually becoming the CSO and became an integral part of the company’s acquisition. More recently, she was Executive Director of Platform Strategy at Quell Therapeutics.

Leigh has a BSc in Biochemistry from Simmons University and a PhD from Imperial College London.